Wells Fargo
LTRN icon

Wells Fargo’s Lantern Pharma LTRN Stock Holding History

Wells Fargo’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,475
Closed -$2.02K – 7475
2026
Q1 		$2.02K Hold
1,475
– – ﹤0.01% 6247
2025
Q4 		$4.47K Sell
1,475
-250
-14% -$931 ﹤0.01% 6123
2025
Q3 		$7.5K Sell
1,725
-3,261
-65% -$13.6K ﹤0.01% 6001
2025
Q2 		$15.8K Sell
4,986
-420
-8% -$1.42K ﹤0.01% 5839
2025
Q1 		$19.1K Buy
5,406
+798
+17% +$3.31K ﹤0.01% 5727
2024
Q4 		$14.7K Sell
4,608
-3,400
-42% -$11.6K ﹤0.01% 5840
2024
Q3 		$29.4K Buy
8,008
+950
+13% +$3.91K ﹤0.01% 5530
2024
Q2 		$33K Sell
7,058
-558
-7% -$3.36K ﹤0.01% 5435
2024
Q1 		$67K Buy
7,616
+3,121
+69% +$16.7K ﹤0.01% 5131
2023
Q4 		$19.2K Buy
4,495
+3
+0.1% +$11 ﹤0.01% 5647
2023
Q3 		$15.3K Buy
4,492
+4
+0.1% +$18 ﹤0.01% 5689
2023
Q2 		$25.3K Buy
4,488
+2
+0% +$10 ﹤0.01% 5671
2023
Q1 		$21.7K Buy
4,486
+501
+13% +$2.63K ﹤0.01% 5606
2022
Q4 		$24.1K Buy
3,985
+1
+0% +$5 ﹤0.01% 5185
2022
Q3 		$19K Buy
3,984
+204
+5% +$1.1K ﹤0.01% 5425
2022
Q2 		$21K Buy
3,780
+222
+6% +$1.32K ﹤0.01% 5424
2022
Q1 		$25K Buy
3,558
+2,326
+189% +$15.5K ﹤0.01% 5938
2021
Q4 		$9K Buy
1,232
+279
+29% +$2.55K ﹤0.01% 6582
2021
Q3 		$11K Sell
953
-6,470
-87% -$83.7K ﹤0.01% 6172
2021
Q2 		$109K Buy
7,423
+3,780
+104% +$58.4K ﹤0.01% 5277
2021
Q1 		$66K Buy
3,643
+3,575
+5,257% +$62.7K ﹤0.01% 5676
2020
Q4 		$1K Buy
68
+57
+518% +$985 ﹤0.01% 6359
2020
Q3 		$0 Buy
+11
New +$159 ﹤0.01% 6654

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Wells Fargo's LTRN Position: Q2 2026 in Review

Wells Fargo sold out of Lantern Pharma (LTRN) in Q2 2026, closing a stake of 1,475 shares — an estimated $2.02K sold.

Wells Fargo first reported a position in LTRN in Q3 2020 and held it in 23 quarters. The position peaked at $109K in Q2 2021. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Wells Fargo reported no remaining Lantern Pharma position as of Q2 2026 after selling out during the quarter.
  • Wells Fargo sold 1,475 Lantern Pharma shares in Q2 2026, an estimated $2.02K.
  • Wells Fargo first reported a position in Lantern Pharma in Q3 2020 and held it in 23 quarters.
  • Wells Fargo's Lantern Pharma position peaked at $109K in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.